XR Securities LLC Has $335,000 Stake in Gilead Sciences, Inc. (GILD)

XR Securities LLC reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 74.6% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 5,160 shares of the biopharmaceutical company’s stock after selling 15,167 shares during the quarter. XR Securities LLC’s holdings in Gilead Sciences were worth $335,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the company. Athena Capital Advisors LLC purchased a new stake in Gilead Sciences during the 4th quarter valued at about $27,000. Capital Financial Planning LLC purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $27,000. Advisors Preferred LLC purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $31,000. Legacy Financial Advisors Inc. lifted its holdings in Gilead Sciences by 361.3% in the 4th quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 383 shares during the period. Finally, Claybrook Capital LLC purchased a new stake in Gilead Sciences in the 4th quarter worth approximately $32,000. Institutional investors own 80.20% of the company’s stock.

Several research firms have weighed in on GILD. Wells Fargo & Co dropped their price objective on Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating for the company in a report on Tuesday, February 5th. Citigroup reaffirmed a “buy” rating and set a $100.00 price objective on shares of Gilead Sciences in a research report on Tuesday, February 5th. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, February 7th. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, January 23rd. Finally, Maxim Group set a $84.00 target price on Gilead Sciences and gave the stock a “buy” rating in a report on Tuesday, February 5th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $82.00.

Shares of NASDAQ GILD traded down $0.98 during trading hours on Wednesday, reaching $63.56. The stock had a trading volume of 160,549 shares, compared to its average volume of 6,597,101. The company has a debt-to-equity ratio of 1.19, a quick ratio of 3.30 and a current ratio of 3.38. The firm has a market capitalization of $83.46 billion, a price-to-earnings ratio of 10.33, a PEG ratio of 4.12 and a beta of 1.16. Gilead Sciences, Inc. has a 52-week low of $60.32 and a 52-week high of $79.61.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing analysts’ consensus estimates of $1.70 by ($0.26). Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter in the prior year, the company earned $1.78 EPS. The firm’s quarterly revenue was down 2.6% on a year-over-year basis. Analysts forecast that Gilead Sciences, Inc. will post 6.23 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were given a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 3.96%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. The ex-dividend date was Thursday, March 14th. Gilead Sciences’s dividend payout ratio is presently 40.98%.

In other Gilead Sciences news, Director John Francis Cogan sold 2,700 shares of the stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $67.23, for a total transaction of $181,521.00. Following the sale, the director now directly owns 57,560 shares of the company’s stock, valued at approximately $3,869,758.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gayle E. Wilson sold 19,068 shares of the stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $67.08, for a total value of $1,279,081.44. Following the sale, the director now directly owns 143,567 shares in the company, valued at $9,630,474.36. The disclosure for this sale can be found here. Over the last three months, insiders sold 39,402 shares of company stock worth $2,613,954. 0.20% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/17/gilead-sciences-inc-gild-shares-sold-by-xr-securities-llc.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Further Reading: Earnings Per Share

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.